公开(公告)号：US20060100446A1

公开(公告)日：2006-05-11

申请号：US11257828

申请日：2005-10-24

申请人： Judith Aronhime ,  Ramy Lidor-Hadas ,  Valerie Niddam-Hildesheim ,  Revital Lifshitz-Liron ,  Shlomit Wizel

发明人： Judith Aronhime ,  Ramy Lidor-Hadas ,  Valerie Niddam-Hildesheim ,  Revital Lifshitz-Liron ,  Shlomit Wizel

IPC分类号： C07D207/24

CPC分类号： C07D207/34 ,  A61K9/282 ,  A61K9/5021 ,  C07D405/06

摘要： The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin.

公开(公告)号：US20060100267A1

公开(公告)日：2006-05-11

申请号：US11257886

申请日：2005-10-24

申请人： Judith Aronhime ,  Ramy Lidor-Hadas ,  Valerie Niddam-Hildesheim ,  Revital Lifshitz-Liron ,  Shlomit Wizel

发明人： Judith Aronhime ,  Ramy Lidor-Hadas ,  Valerie Niddam-Hildesheim ,  Revital Lifshitz-Liron ,  Shlomit Wizel

IPC分类号： A61K31/401 ,  C07D207/24

CPC分类号： C07D207/34 ,  A61K9/282 ,  A61K9/5021 ,  C07D405/06

摘要： The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin.

公开(公告)号：US20070265456A1

公开(公告)日：2007-11-15

申请号：US11431183

申请日：2006-05-09

申请人： Judith Aronhime ,  Ramy Lidor-Hadas ,  Valerie Niddam-Hildesheim ,  Shlomit Wizel ,  Revital Lifshitz-Liron ,  Michael Pinchasov

发明人： Judith Aronhime ,  Ramy Lidor-Hadas ,  Valerie Niddam-Hildesheim ,  Shlomit Wizel ,  Revital Lifshitz-Liron ,  Michael Pinchasov

IPC分类号： C07D207/30

CPC分类号： C07D207/34 ,  C07D405/06 ,  C07D493/04

摘要： The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin. Also provided is atorvastatin hemi-calcium Form VIII that is stable against the formation of atorvastatin hemi-calcium is atorvastatin calcium epoxy dihydroxy (AED).

摘要翻译： 本发明提供命名为形式VI，VIII，IX，X，XI和XII的阿托伐他汀的新形式及其制备方法以及制备阿托伐他汀形式I，II，IV，V和无定形阿托伐他汀的方法。 还提供了对阿托伐他汀半钙形成稳定的阿伐他汀半钙形式VIII是阿托伐他汀钙环氧二羟基（AED）。

公开(公告)号：US20060106232A1

公开(公告)日：2006-05-18

申请号：US11257815

申请日：2005-10-24

申请人： Judith Aronhime ,  Ramy Lidor-Hadas ,  Valerie Niddam-Hildesheim ,  Revital Lifshitz-Liron ,  Shlomit Wizel

发明人： Judith Aronhime ,  Ramy Lidor-Hadas ,  Valerie Niddam-Hildesheim ,  Revital Lifshitz-Liron ,  Shlomit Wizel

IPC分类号： C07D207/333

CPC分类号： C07D207/34 ,  A61K9/282 ,  A61K9/5021 ,  C07D405/06

摘要： The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin.

公开(公告)号：US20060106231A1

公开(公告)日：2006-05-18

申请号：US11257808

申请日：2005-10-24

申请人： Judith Aronhime ,  Ramy Lidor-Hadas ,  Valerie Niddam-Hildesheim ,  Revital Lifshitz-Liron ,  Shlomit Wizel

发明人： Judith Aronhime ,  Ramy Lidor-Hadas ,  Valerie Niddam-Hildesheim ,  Revital Lifshitz-Liron ,  Shlomit Wizel

IPC分类号： C07D207/333

CPC分类号： C07D207/34 ,  A61K9/282 ,  A61K9/5021 ,  C07D405/06

摘要： The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin.

公开(公告)号：US20060100445A1

公开(公告)日：2006-05-11

申请号：US11257821

申请日：2005-10-24

申请人： Judith Aronhime ,  Ramy Lidor-Hadas ,  Valerie Niddam-Hildesheim ,  Revital Lifshitz-Liron ,  Shlomit Wizel

发明人： Judith Aronhime ,  Ramy Lidor-Hadas ,  Valerie Niddam-Hildesheim ,  Revital Lifshitz-Liron ,  Shlomit Wizel

IPC分类号： C07D207/24

CPC分类号： C07D207/34 ,  A61K9/282 ,  A61K9/5021 ,  C07D405/06

摘要： The present invention provides novel forms of atorvastatin designated Forms VI, VIII, IX, X, XI and XII and novel processes for their preparation as well as processes for preparing atorvastatin Forms I, II, IV, V and amorphous atorvastatin.

公开(公告)号：US20050187229A1

公开(公告)日：2005-08-25

申请号：US11042526

申请日：2005-01-25

申请人： Shlomit Wizel ,  Judith Aronhime ,  Valerie Niddam-Hildesheim ,  Ben-Zion Dolitzky ,  Marina Etinger ,  Michael Yuzefovich ,  Gennady Nisnevich ,  Boris Pertsikov ,  Boris Tishin ,  Dina Blasberger

发明人： Shlomit Wizel ,  Judith Aronhime ,  Valerie Niddam-Hildesheim ,  Ben-Zion Dolitzky ,  Marina Etinger ,  Michael Yuzefovich ,  Gennady Nisnevich ,  Boris Pertsikov ,  Boris Tishin ,  Dina Blasberger

IPC分类号： C07D473/18 ,  A61K31/522 ,  A61P31/12 ,  A61P43/00 ,  C07D473/00 ,  C07D473/10

CPC分类号： C07D473/00 ,  A61K31/522 ,  C07D473/18

摘要： Provided are novel polymorphs and pseudopolymorphs of valacyclovir hydrochloride and pharmaceutical compositions containing these. Also provided are methods for making the novel polymorphs and pseudopolymorphs, which include valacyclovir hydrochloride monohydrate and valacyclovir hydrochloride dihydrate.

公开(公告)号：US20050043329A1

公开(公告)日：2005-02-24

申请号：US10791451

申请日：2004-03-01

申请人： Shlomit Wizel ,  Judith Aronhime ,  Valerie Niddam-Hildesheim ,  Ben-Zion Dolitzky ,  Marina Etinger ,  Michael Yuzefovich ,  Gennady Nisnevich ,  Boris Pertsikov ,  Boris Tishin ,  Dina Blasberger

发明人： Shlomit Wizel ,  Judith Aronhime ,  Valerie Niddam-Hildesheim ,  Ben-Zion Dolitzky ,  Marina Etinger ,  Michael Yuzefovich ,  Gennady Nisnevich ,  Boris Pertsikov ,  Boris Tishin ,  Dina Blasberger

IPC分类号： A61K31/522 ,  C07D473/00 ,  C07D473/18

CPC分类号： A61K31/522 ,  C07D473/00 ,  C07D473/18

摘要： Provided are novel crystalline forms of valacyclovir hydrochloride, in particular a novel hydrated form of valacyclovir hydrochloride having about 6% to about 10% by weight water. Also provided are methods for making the novel crystalline forms.

摘要翻译： 提供盐酸伐昔洛韦的新型结晶形式，特别是具有约6％至约10％重量水的新型水合形式的盐酸伐昔洛韦。 还提供了制备新型结晶形式的方法。

公开(公告)号：US06849736B2

公开(公告)日：2005-02-01

申请号：US10236729

申请日：2002-09-06

申请人： Shlomit Wizel ,  Judith Aronhime ,  Valerie Niddam-Hildesheim ,  Ben-Zion Dolitzky ,  Marina Yu Etinger ,  Michael Yuzefovich ,  Gennady A. Nisnevich ,  Boris Pertsikov ,  Boris Tishin ,  Dina Blasberger

发明人： Shlomit Wizel ,  Judith Aronhime ,  Valerie Niddam-Hildesheim ,  Ben-Zion Dolitzky ,  Marina Yu Etinger ,  Michael Yuzefovich ,  Gennady A. Nisnevich ,  Boris Pertsikov ,  Boris Tishin ,  Dina Blasberger

IPC分类号： C07D473/18 ,  A61K31/522 ,  A61P31/12 ,  A61P43/00 ,  C07D473/00

CPC分类号： C07D473/00 ,  A61K31/522 ,  C07D473/18

摘要： Provided are novel polymorphs and pseudopolymorphs of valacyclovir hydrochloride and pharmaceutical compositions containing these. Also provided are methods for making the novel polymorphs and pseudopolymorphs, which include valacyclovir hydrochloride monohydrate and valacyclovir hydrochloride dihydrate.

摘要翻译： 提供了盐酸伐昔洛韦的新型多晶型物和假多晶型物，以及含有它们的药物组合物。 还提供了制备新型多晶型物和假多晶型物的方法，其包括盐酸伐昔洛韦一水合物和盐酸伐昔洛韦二水合物。

公开(公告)号：US20050197501A1

公开(公告)日：2005-09-08

申请号：US11120567

申请日：2005-05-02

申请人： Valerie Niddam-Hildesheim ,  Revital Lifshitz-Liron ,  Rami Lidor-Hadas

发明人： Valerie Niddam-Hildesheim ,  Revital Lifshitz-Liron ,  Rami Lidor-Hadas

IPC分类号： A61K20060101 ,  C07D207/34 ,  C07D209/24 ,  C07D213/55 ,  C07D215/14 ,  C07D239/42 ,  C07D309/30 ,  C07D405/06 ,  C07F20060101 ,  C07C69/66

CPC分类号： C07D207/34 ,  C07D209/24 ,  C07D213/55 ,  C07D215/14 ,  C07D239/42 ,  C07D309/30 ,  C07D405/06 ,  Y02P20/55

摘要： Processes for preparing a calcium salt of a statin from an ester derivative or protected ester derivative of the statin by using calcium hydroxide are provided. The ester or protected ester derivative is contacted with calcium hydroxide to obtain the calcium salt. Preferred statins are rosuvastatin, pitavastatin and atorvastatin, simvastatin and lovastatin. In processes beginning with a protected statin ester derivative, the protecting group is hydrolyzed during salt formation by contact with calcium hydroxide, or is contacted with an acid catalyst followed by contact with calcium hydroxide.

摘要翻译： 提供了通过使用氢氧化钙从他汀类的酯衍生物或被保护的酯衍生物制备他汀类钙盐的方法。 将酯或保护的酯衍生物与氢氧化钙接触以获得钙盐。 优选的他汀类是瑞舒伐他汀，匹伐他汀和阿托伐他汀，辛伐他汀和洛伐他汀。 在以受保护的他汀类酯衍生物开始的方法中，保护基在与氢氧化钙接触的盐形成过程中水解，或者与酸催化剂接触，然后与氢氧化钙接触。